Eterna Therapeutics Inc
$ 0.20
-5.34%
10 Apr - close price
- Market Cap 6,008,700 USD
- Current Price $ 0.20
- High / Low $ 0.21 / 0.20
- Stock P/E N/A
- Book Value 0.31
- EPS -2.12
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.05 %
- ROE -6.87 %
- 52 Week High 4.05
- 52 Week Low 0.18
About
Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.
Analyst Target Price
$3.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-13 | 2025-05-07 | 2025-03-12 | 2023-11-13 | 2023-08-11 | 2023-05-11 | 2023-03-20 | 2022-11-14 | 2022-08-11 | 2022-04-15 | 2021-12-31 |
| Reported EPS | -0.15 | -0.61 | -2.31 | -0.15 | -1.0335 | -0.8516 | -1.24 | -1.24 | -2.49 | -1.2 | -3.2 | -3.2 |
| Estimated EPS | 0 | 0 | 0 | 0 | None | None | -0.14 | -0.14 | -2.2 | -2.6 | -2.5 | -37.5 |
| Surprise | -0.15 | -0.61 | -2.31 | -0.15 | 0 | 0 | -1.1 | -1.1 | -0.29 | 1.4 | -0.7 | 34.3 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | -785.7143% | -785.7143% | -13.1818% | 53.8462% | -28% | 91.4667% |
Next Quarterly Earnings
| Apr 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ERNA
2026-04-04 15:40:05
This article analyzes the valuation of Ernexa Therapeutics Inc (ERNA), stating that the stock is currently in the "Fair zone" based on its forward PS ratio of 0.00 compared to a five-year average of -3.19. It details various valuation metrics such as P/B ratio and FCF yield, comparing them to historical averages and industry benchmarks. The analysis also questions the sustainability of its P/S ratio premium given a reported -100.00% revenue growth.
2026-04-01 22:40:05
Ernexa Therapeutics (NASDAQ: ERNA) has approved a board-authorized reverse stock split at a ratio between 1-for-10 and 1-for-25. This action, approved by shareholders representing 51.63% of voting power, aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The reverse split will become effective no earlier than 20 calendar days after the information statement is mailed to shareholders, with the exact ratio to be determined by the Board.
2026-04-01 10:39:53
Ernexa Therapeutics announced significant progress in advancing its lead engineered iMSC therapy, ERNA-101, towards first-in-human trials in Q4 2026, with an IND submission targeted for Q3 2026. Preclinical data for ERNA-101 combined with PD-1 blockade showed high rates of complete tumor regressions and prolonged survival in ovarian cancer models. The company also highlighted a $10.5 million financing and a 61% reduction in G&A expenses in 2025, positioning them for key clinical development milestones.
2026-03-31 13:39:34
Ernexa Therapeutics is progressing its lead product candidate, ERNA-101, towards first-in-human clinical trials in Q4 2026 for platinum-resistant ovarian cancer. Preclinical data shows ERNA-101, combined with PD-1 blockade, leads to deep and durable tumor regressions. The company is actively working on an IND submission for Q3 2026 and expects multiple regulatory and clinical milestones in the next 12-18 months, supported by recent financing.
2026-03-31 10:39:53
This article announces that an SEC filing for Ernexa Therapeutics Inc. has been declared "EFFECTive." The filing is Form S-3, a shelf registration statement, which became effective on March 30, 2026, at 4:30 P.M. The filing indicates a neutral impact and sentiment according to Rhea-AI.
2026-03-31 08:55:00
Ernexa Therapeutics is advancing its lead product candidate, ERNA-101, toward first-in-human clinical trials for platinum-resistant ovarian cancer in Q4 2026, with an IND submission expected in Q3 2026. Preclinical data show that ERNA-101 combined with PD-1 blockade leads to deep and durable tumor regressions. The company is also developing ERNA-201 for autoimmune diseases and anticipates several regulatory and clinical milestones to drive value over the next 12-18 months.
